The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biologic Spending & Price Trends

Biologic Spending & Price Trends

January 28, 2020 • By Arthritis & Rheumatology

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Introduction & Objectives
Over the past two decades since biologic disease-modifying anti-rheumatic drugs (DMARDs) were first approved by the U.S. Federal Drug Administration (FDA), they have improved the health and productivity of many patients with moderate-to-severe rheumatoid arthritis, psoriasis/psoriatic arthritis, ankylosing spondylitis, lupus, systemic vasculitis and other rheumatic and autoimmune diseases, which together affect more than 1 million Medicare beneficiaries. However, due to their high prices ($22,000–44,000 per patient annually) and placement in specialty tiers with high levels of cost-sharing, biologic DMARDs pose substantial financial burdens for patients and taxpayers.

You Might Also Like
  • U.S. Healthcare Spending to Climb 5.3 Percent in 2018
  • U.S. Predicts 5.8% Average Rise in Healthcare Spending Through 2024
  • U.S. Health Agency Estimates 2015 Prescription Drug Spending Rose to $457 Billion

Three biologic agents (adalimumab, etanercept and infliximab) have been ranked among the top five prescription medications in the U.S. for the greatest total spending.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Billions of public dollars are spent each year on biologic DMARDs, but the drivers of recent increases in biologic DMARD spending are unclear. This study was undertaken to characterize changes in total spending and unit prices for biologic DMARDs used in the treatment of rheumatic diseases in Medicare and Medicaid programs and quantify the major sources of these spending increases.

Methods
The authors accessed drug spending data from 2012–16 for Medicare Part B (fee-for-service), Medicare Part D and Medicaid enrollees. After calculating five-year changes in total spending and unit prices for each biologic DMARD, as well as in aggregate, the researchers performed standard decomposition analyses to isolate four sources of spending growth: drug prices, uptake (number of recipients), treatment intensity (mean number of doses per claim), and treatment duration (annual number of claims per recipient), both excluding and including time-varying rebates.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Results
From 2012 to 2016, annual spending on public-payer claims for the 10 biologic DMARDs included in this study more than doubled ($3.8 billion to $8.6 billion), with median drug price increases of 51% in Medicare Part D (mean 54%) and 8% in Medicare Part B (mean 21%). With adjustment for general inflation, unit price increases alone accounted for 57% of the five-year, $3.0 billion spending increase in Part D, while 37% of the spending increase was from increased uptake. Accounting for time-varying rebates, prices were still responsible for 54% of increased spending. Unit prices and spending were lower under Medicaid than under Medicare Part D, though temporal trends and contributors were similar.

Conclusion
Postmarket drug price changes alone account for the majority of the recent spending growth in biologic DMARDs.

The recent introduction of biosimilars could foster more competition and lower prices in theory, but as of August 2019, only two of nine FDA-approved DMARD biosimilars (infliximab-dyyb and infliximab-abda) were being marketed in the U.S.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: adalimumab, biologic drugs, Disease-modifying antirheumatic drugs (DMARDs), etanercept, infliximab

You Might Also Like:
  • U.S. Healthcare Spending to Climb 5.3 Percent in 2018
  • U.S. Predicts 5.8% Average Rise in Healthcare Spending Through 2024
  • U.S. Health Agency Estimates 2015 Prescription Drug Spending Rose to $457 Billion
  • Medicare Switch to ASP Pricing Reduces Part B Spending

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.